ocgn-20200716xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020 Forward Looking Statement This presentation contains forward-looking statements that involve

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020

Ocugen's Modifier Gene Therapy Platform Breakthrough Technology designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 6

OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet Age-Related Macular Degeneration (Wet AMD) Novel Biologic Offering Benefits Beyond Anti-VEGF 17

A Bold Vision to Cure Blindness Diseases with Gene Therapies For more information, contact: IR@ocugen.com